Chinese herbal medicine for diabetic kidney disease: a systematic review and meta-analysis of randomised placebo-controlled trials.
La Zhang,Lihong Yang,Johannah Linda Shergis,Lei Zhang,Anthony Lin Zhang,Xinfeng Guo,Xindong Qin,David W. Johnson,Xusheng Liu,Chuanjian Lu,Charlie Changli Xue,Wei Mao +11 more
Reads0
Chats0
TLDR
Based on moderate to low quality evidence, CHM may have beneficial effects on renal function and albuminuria beyond that afforded by conventional treatment in adults with DKD.Abstract:
Objectives To provide a broad evaluation of the efficacy and safety of oral Chinese herbal medicine (CHM) as an adjunctive treatment for diabetic kidney disease (DKD), including mortality, progression to end-stage kidney disease (ESKD), albuminuria, proteinuria and kidney function. Design A systematic review and meta-analysis. Methods Randomised controlled trials (RCTs) comparing oral CHM with placebo as an additional intervention to conventional treatments were retrieved from five English (Cochrane Central Register of Controlled Trials, MEDLINE, Embase, Allied and Complementary Medicine Database and Cumulative Index of Nursing and Allied Health Literature) and four Chinese databases (China BioMedical Literature, China National Knowledge Infrastructure, Chonqing VIP and Wanfang) from inception to May 2018. RCTs recruiting adult DKD patients induced by primary diabetes were considered eligible, regardless of the form and ingredients of oral CHM. Mean difference (MD) or standardised mean difference (SMD) was used to analyse continuous variables and RR for dichotomous data. Results From 7255 reports retrieved, 20 eligible studies involving 2719 DKD patients were included. CHM was associated with greater reduction of albuminuria than placebo, regardless of whether renin–angiotensin system (RAS) inhibitors were concurrently administered (SMD −0.56, 95% CI [−1.04 to –0.08], I2=64%, p=0.002) or not (SMD −0.92, 95% CI [−1.35 to –0.51], I2=87%, p Conclusions Based on moderate to low quality evidence, CHM may have beneficial effects on renal function and albuminuria beyond that afforded by conventional treatment in adults with DKD. Further well-conducted, adequately powered trials with representative DKD populations are warranted to confirm the long-term effect of CHM, particularly on clinically relevant outcomes. PROSPERO registration number CRD42015029293.read more
Citations
More filters
Journal ArticleDOI
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020.
TL;DR: The present paper presents a meta-analysis of 148 cases of type 2 diabetes patients treated at the UCMS-GTB Hospital in Ahmedabad over a 12-month period from May 2013 to March 2014 that showed clear trends in disease progression and in particular in cases of high blood pressure and insulin resistance.
Journal ArticleDOI
Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
TL;DR: The clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN are summarized after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses.
Journal ArticleDOI
The Efficacy and Mechanism of Chinese Herbal Medicine on Diabetic Kidney Disease.
TL;DR: The progress of Chinese herbal medicine (CHM) in the treatment of DKD is summarized from two aspects: in clinical trials, the Chinese herbal formulas were efficacy and safety confirmed by the randomized controlled trials, and in experimental research, studies provided evidence for the efficacy of CHM.
Journal ArticleDOI
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
TL;DR: The present paper presents a meta-analysis of 148 cases of type 2 diabetes patients treated at the UCMS-GTB Hospital in Ahmedabad over a 12-month period from May 2013 to March 2014 that showed clear trends in disease progression and in particular in cases of high blood pressure and insulin resistance.
Journal ArticleDOI
Chinese Herbal Medicine in Ameliorating Diabetic Kidney Disease via Activating Autophagy.
Yuyang Wang,Hailing Zhao,Qian Wang,Qian Wang,Xuefeng Zhou,Xuefeng Zhou,Xiaoguang Lu,Tongtong Liu,Yongli Zhan,Ping Li +9 more
TL;DR: Wang et al. as mentioned in this paper summarized underlying mechanisms of autophagy dysregulation in diabetic kidney disease, including AMP-activated protein kinase (AMPK), the mechanistic target of rapamycin (mTOR), and the sirtuin (Sirt) pathways.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
TL;DR: A structured summary is provided including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings.
Journal ArticleDOI
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
Julian P T Higgins,Douglas G. Altman,Peter C Gøtzsche,Peter Jüni,David Moher,Andrew D Oxman,Jelena Savović,Kenneth F. Schulz,Laura Weeks,Jonathan A C Sterne +9 more
TL;DR: The Cochrane Collaboration’s tool for assessing risk of bias aims to make the process clearer and more accurate.